+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Orphan Drugs Market - Global Forecast 2026-2032- Product Image
Orphan Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Orphan Drugs Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674387
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Orphan Drugs Market is projected to reach USD 213.45 Billion in 2026. It is expected to continue growing at a CAGR of 11.96%, reaching USD 421.32 Billion by 2032.

The orphan drugs market is expanding as governments, regulators, biopharmaceutical developers, healthcare systems, and patient organizations intensify efforts to address rare diseases with high unmet medical need. Rare diseases collectively affect an estimated 300 million people worldwide, including about 30 million people in the United States, while more than 7,000 rare diseases have been identified. Despite scientific progress, widely cited public health estimates indicate that approximately 95% of rare diseases still lack an approved treatment, creating a durable innovation gap for orphan drug discovery and development.

Momentum is supported by established incentive frameworks such as the U.S. Orphan Drug Act, which applies to conditions affecting fewer than 200,000 people in the United States, and the European Union orphan designation pathway for life-threatening or chronically debilitating diseases affecting no more than 5 in 10,000 people. These policies, combined with regulatory exclusivity, tax credits or fee reductions in select jurisdictions, accelerated pathways, and stronger biomarker science, continue to make orphan drugs a strategically important segment of the global pharmaceutical industry.

Transformative Shifts in the Orphan Drug Landscape

The orphan drugs landscape is shifting from traditional small-molecule and enzyme replacement approaches toward precision biologics, gene therapies, RNA-based medicines, and cell-based interventions. Advances in genomics, newborn screening, natural history studies, and real-world evidence are improving disease identification and trial design, enabling sponsors to pursue smaller but more targeted patient populations with clearer clinical endpoints.

Commercial models are also changing. Orphan drugs often serve limited populations, but development programs face complex manufacturing, evidence-generation, access, and reimbursement requirements. Payers are increasingly demanding outcomes-based evidence, long-term durability data, and transparent value justification, particularly for one-time or high-cost therapies. At the same time, patient advocacy groups are becoming central partners in registries, trial recruitment, endpoint selection, and post-approval evidence generation.

Regulatory agencies are placing greater emphasis on confirmatory studies, safety surveillance, and clinically meaningful benefit. As a result, successful participants in orphan drug development are integrating regulatory strategy, health economics, patient engagement, and global access planning much earlier in the product lifecycle.

Cumulative Impact of Artificial Intelligence on Orphan Drugs

Artificial intelligence is accelerating orphan drug discovery by improving target identification, phenotype matching, literature mining, protein modeling, and drug repurposing. Because rare disease research often suffers from fragmented datasets and small patient cohorts, AI-enabled analytics can help connect genomic variants, clinical histories, imaging, and registry data to reveal disease mechanisms that may otherwise remain hidden.

AI is also influencing clinical development. Machine learning models support patient stratification, site selection, synthetic control arm design, and real-world evidence analysis, helping reduce trial delays in ultra-rare indications. In diagnosis, AI-enabled clinical decision support and natural language processing can shorten the diagnostic odyssey by flagging rare disease patterns across electronic health records, claims data, and laboratory findings.

The impact is cumulative rather than isolated: each improvement in diagnosis, data integration, trial design, and post-market monitoring strengthens the evidence ecosystem. However, industry leaders must address bias, data privacy, interoperability, explainability, and regulatory validation to ensure AI-driven orphan drug development remains scientifically credible and patient-centered.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

North America remains a leading region for orphan drug innovation, supported by the U.S. Food and Drug Administration’s mature designation framework, deep biomedical financing, academic medical centers, clinical trial infrastructure, and established patient advocacy networks. The United States is particularly influential in rare disease policy, regulatory science, clinical development, and reimbursement discussions, while Canada continues to strengthen rare disease access through national policy initiatives, health technology assessment, and provincial reimbursement mechanisms.

Europe is defined by coordinated regulation, advanced health technology assessment systems, and the European Medicines Agency’s orphan designation pathway. The European Union provides scientific advice, protocol assistance, and market exclusivity incentives, although country-by-country pricing and reimbursement decisions can create access variability. The United Kingdom, Germany, France, Italy, and Spain remain important rare disease markets due to specialist centers, registry activity, and established assessment systems. Russia has designated rare disease funding mechanisms in select areas, but access is shaped by procurement policy, reimbursement constraints, and geopolitical complexity.

Asia-Pacific is gaining importance as Japan, China, South Korea, Australia, and India expand rare disease policies, genetic testing capacity, clinical research infrastructure, and expedited review pathways. Japan has a long-standing orphan drug framework, China has introduced rare disease lists and priority review mechanisms, South Korea supports advanced biopharma innovation, Australia benefits from mature regulatory standards, and India’s national rare disease policy has increased public attention to affordability and diagnosis. Latin America, the Middle East, and Africa present meaningful long-term opportunities but face uneven diagnostic capacity, reimbursement constraints, and limited specialist access. Brazil and Mexico are important Latin American markets, GCC countries are investing in specialty care and genomics, and African markets increasingly rely on public health partnerships, newborn screening expansion, donor-supported diagnostics, and regional centers of excellence to improve rare disease care.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are emerging as important access and diagnosis frontiers for orphan drugs, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines at different stages of rare disease policy development. Regional progress is supported by growing genomic medicine capacity, specialist centers, newborn screening programs, and cross-border clinical collaboration, although reimbursement consistency and affordability remain major challenges across lower- and middle-income settings.

The GCC is investing in precision medicine, national genome programs, and specialty hospital infrastructure, which is highly relevant given the higher observed burden of some inherited disorders in populations with consanguinity. The European Union remains a benchmark for orphan designation, coordinated scientific assessment, European reference networks, and rare disease policy collaboration, while also facing increasing pressure to balance innovation incentives with affordability, equitable access, and evidence requirements for advanced therapies.

BRICS countries represent large patient populations and expanding clinical trial potential, but access depends on local regulatory modernization, domestic manufacturing priorities, public reimbursement design, and the availability of genetic testing. G7 countries continue to shape global orphan drug policy, pricing expectations, health technology assessment standards, and evidence generation norms through mature regulatory agencies and advanced biomedical research systems. NATO membership is not a health-market category, yet many NATO countries are high-income economies with strong biomedical systems that support rare disease research, preparedness, medicine security, and resilient pharmaceutical supply chains.

Key Country Insights for Major Orphan Drug Markets

The United States leads global orphan drug commercialization through FDA incentives, strong biomedical investment, advanced research hospitals, clinical trial networks, and a large rare disease advocacy ecosystem. Canada offers an important access market with centralized health technology assessment and provincial reimbursement dynamics, while Mexico and Brazil are key Latin American countries where regulatory modernization, public procurement, specialist centers, and public-private specialty care networks influence orphan drug uptake.

In Europe, the United Kingdom combines strong genomics assets, the National Health Service, and health technology assessment through national reimbursement processes. Germany remains an important early-launch market due to its structured reimbursement pathway, while France, Italy, and Spain provide significant patient populations and specialist care networks but require robust clinical and economic evidence. Russia has rare disease reimbursement programs in select areas, though market access is affected by policy, procurement, localization requirements, and geopolitical complexity.

In Asia-Pacific, China is rapidly expanding rare disease lists, priority review mechanisms, clinical research activity, and domestic innovation, while India offers a large genetic disease burden and improving policy attention but faces affordability, diagnostic, and reimbursement barriers. Japan has a mature orphan drug system supported by established regulatory incentives and specialist care, South Korea supports advanced biopharma innovation and expedited pathways, and Australia combines strong regulatory standards with growing rare disease policy coordination, newborn screening activity, patient registries, and specialist care infrastructure.

Actionable Recommendations for Orphan Drug Industry Leaders

Industry leaders should prioritize evidence strategies that begin before pivotal trials, including natural history studies, patient registries, validated biomarkers, patient-reported outcomes, and real-world evidence plans. These assets improve regulatory dialogue, support health technology assessment, and strengthen payer negotiations in small-population indications where randomized trial data may be limited.

Organizations should also build patient-centered development models by partnering with advocacy groups, reducing trial burden, improving genetic testing access, enabling decentralized trial components where appropriate, and aligning endpoints with outcomes that matter to patients and caregivers. For advanced therapies, manufacturers must prepare scalable quality systems, cold-chain logistics, long-term follow-up protocols, pharmacovigilance plans, and clear durability evidence.

Commercial success will increasingly depend on integrated global access planning. Leaders should evaluate value-based agreements, managed entry models, early access programs, differential access pathways, and country-specific reimbursement evidence. Strategic use of AI should focus on explainable, validated applications in diagnosis, trial recruitment, pharmacovigilance, and portfolio prioritization, with strong governance for privacy, bias mitigation, data provenance, and data quality.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified public-domain and industry-recognized sources. Core inputs include regulatory definitions and guidance from the U.S. Food and Drug Administration and European Medicines Agency, rare disease prevalence references from public health and patient advocacy organizations, and policy information from national regulatory, reimbursement, and health technology assessment agencies.

The methodology applies triangulation across regulatory documents, peer-reviewed literature, clinical trial databases, health technology assessment frameworks, public disclosures, and credible rare disease organizations. Market interpretation emphasizes data-backed signals such as orphan designation criteria, prevalence thresholds, treatment gaps, regulatory incentives, clinical development trends, evidence requirements, and regional access conditions.

Insights are synthesized through an executive-summary lens that evaluates market structure, innovation drivers, policy dynamics, geographic opportunity, and strategic implications. The analysis avoids unsupported projections and focuses on verifiable factors shaping orphan drug discovery, development, approval, reimbursement, and patient access.

Conclusion

The orphan drugs market is positioned for sustained strategic relevance as scientific innovation converges with regulatory incentives, patient advocacy, and growing global recognition of rare disease burden. The strongest opportunities are emerging where genomics, AI-enabled discovery, advanced therapies, and real-world evidence combine to address conditions with limited or no approved treatment options.

However, the market is also entering a more demanding phase. Payers and regulators are seeking stronger evidence of clinical benefit, durability, safety, and value, especially for high-cost and potentially curative therapies. Organizations that can integrate patient insight, rigorous data generation, manufacturing readiness, and access planning from the earliest stages will be best positioned to succeed.

In this environment, orphan drug leadership will depend not only on breakthrough science but also on equitable diagnosis, credible evidence, responsible pricing, and cross-stakeholder collaboration that turns rare disease innovation into measurable patient impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Orphan Drugs Market, by Therapeutic Area
7.1. Introduction
7.2. Immunology
7.3. Infectious Diseases
7.4. Metabolic Disorders
7.5. Neurology
7.6. Oncology
8. Orphan Drugs Market, by Product Type
8.1. Introduction
8.2. Biologics
8.2.1. Enzymes
8.2.2. Monoclonal Antibodies
8.2.3. Recombinant Proteins
8.3. Gene Therapy
8.3.1. Non-Viral Vector
8.3.2. Viral Vector
8.4. Small-Molecule
8.5. Tissue Therapy
9. Orphan Drugs Market, by Administration Route
9.1. Introduction
9.2. Inhalation
9.3. Injectable
9.3.1. Intramuscular
9.3.2. Intravenous
9.3.3. Subcutaneous
9.4. Oral
9.5. Topical
10. Orphan Drugs Market, by Patient Type
10.1. Introduction
10.2. Adult
10.3. Pediatric
10.4. Geriatric
11. Orphan Drugs Market, by Payer Type
11.1. Introduction
11.2. Government Programs
11.3. Out-Of-Pocket
11.4. Private Insurance
12. Orphan Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Orphan Drugs Market, by End User
13.1. Introduction
13.2. Hospitals
13.3. Specialty Clinics
13.4. Research Institutes
13.5. Homecare Settings
14. Orphan Drugs Market, by Region
14.1. Asia-Pacific
14.2. Europe
14.3. North America
14.4. Latin America
14.5. Africa
14.6. Middle East
15. Orphan Drugs Market, by Group
15.1. NATO
15.2. G7
15.3. European Union
15.4. BRICS
15.5. ASEAN
15.6. GCC
16. Orphan Drugs Market, by Country
16.1. United States
16.2. China
16.3. Germany
16.4. Japan
16.5. India
16.6. United Kingdom
16.7. France
16.8. Canada
16.9. Italy
16.10. Australia
16.11. South Korea
16.12. Brazil
16.13. Mexico
16.14. Russia
16.15. Spain
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc
18.2. Alexion Pharmaceuticals Inc
18.3. Alnylam Pharmaceuticals Inc
18.4. Amgen Inc
18.5. Astellas Pharma Inc
18.6. AstraZeneca PLC
18.7. Bayer AG
18.8. BioMarin Pharmaceutical Inc
18.9. Bristol-Myers Squibb Company
18.10. Daiichi Sankyo Co Ltd
18.11. F. Hoffmann-La Roche Ltd
18.12. FGK Clinical Research GmbH
18.13. Gilead Sciences Inc
18.14. GlaxoSmithKline PLC
18.15. Incyte Corporation
18.16. Ipsen Pharma
18.17. Johnson & Johnson Services Inc
18.18. Kyowa Kirin Co Ltd
18.19. Novartis AG
18.20. Novo Nordisk AS
18.21. Pfizer Inc
18.22. Recordati SpA
18.23. Regeneron Pharmaceuticals Inc
18.24. Sanofi SA
18.25. Sarepta Therapeutics Inc
18.26. Swedish Orphan Biovitrum AB
18.27. Takeda Pharmaceutical Company Limited
18.28. UCB SA
18.29. Ultragenyx Pharmaceutical Inc
18.30. Vertex Pharmaceuticals Incorporated
List of Figures
FIGURE 1. GLOBAL ORPHAN DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ORPHAN DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ORPHAN DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ORPHAN DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ORPHAN DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ORPHAN DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL ORPHAN DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL ORPHAN DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ORPHAN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ENZYMES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ENZYMES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ENZYMES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL NON-VIRAL VECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL NON-VIRAL VECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL NON-VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SMALL-MOLECULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SMALL-MOLECULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SMALL-MOLECULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL TISSUE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL TISSUE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL TISSUE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL INHALATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL GOVERNMENT PROGRAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL GOVERNMENT PROGRAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL GOVERNMENT PROGRAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL OUT-OF-POCKET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL OUT-OF-POCKET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL OUT-OF-POCKET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL PRIVATE INSURANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PRIVATE INSURANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PRIVATE INSURANCE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 121. EUROPE ORPHAN DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. EUROPE ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 123. EUROPE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 124. EUROPE ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 125. EUROPE ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 126. EUROPE ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 127. EUROPE ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 128. EUROPE ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 129. EUROPE ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 130. EUROPE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 131. EUROPE ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. AFRICA ORPHAN DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. AFRICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 156. AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 157. AFRICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 158. AFRICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 159. AFRICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 160. AFRICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 161. AFRICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 162. AFRICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 163. AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. AFRICA ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 165. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 166. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 167. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 177. NATO ORPHAN DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 178. NATO ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 179. NATO ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 180. NATO ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 181. NATO ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 182. NATO ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 183. NATO ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 184. NATO ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 185. NATO ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 186. NATO ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 187. NATO ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. G7 ORPHAN DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. G7 ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 190. G7 ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 191. G7 ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 192. G7 ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 193. G7 ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 194. G7 ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 195. G7 ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 196. G7 ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 197. G7 ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 198. G7 ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 210. BRICS ORPHAN DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 211. BRICS ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 212. BRICS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 213. BRICS ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 214. BRICS ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 215. BRICS ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 216. BRICS ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 217. BRICS ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 218. BRICS ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 219. BRICS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 220. BRICS ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 221. ASEAN ORPHAN DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 222. ASEAN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 223. ASEAN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 224. ASEAN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 225. ASEAN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 226. ASEAN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 227. ASEAN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 228. ASEAN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 229. ASEAN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 230. ASEAN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. ASEAN ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. GCC ORPHAN DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 233. GCC ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 234. GCC ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 235. GCC ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 236. GCC ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 237. GCC ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 238. GCC ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 239. GCC ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 240. GCC ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 241. GCC ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 242. GCC ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 247. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 248. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 249. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 250. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 251. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 252. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 253. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. CHINA ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. CHINA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 257. CHINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 258. CHINA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 259. CHINA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 260. CHINA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 261. CHINA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 262. CHINA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 263. CHINA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 264. CHINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. CHINA ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 266. GERMANY ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 267. GERMANY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 268. GERMANY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 269. GERMANY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 270. GERMANY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 271. GERMANY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 272. GERMANY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 273. GERMANY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 274. GERMANY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 275. GERMANY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 276. GERMANY ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 277. JAPAN ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 278. JAPAN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 279. JAPAN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 280. JAPAN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 281. JAPAN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 282. JAPAN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 283. JAPAN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 284. JAPAN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 285. JAPAN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 286. JAPAN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 287. JAPAN ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 288. INDIA ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. INDIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 290. INDIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 291. INDIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 292. INDIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 293. INDIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 294. INDIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 295. INDIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 296. INDIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 297. INDIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 298. INDIA ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 301. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 302. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 303. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 304. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 307. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 308. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 309. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 310. FRANCE ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 311. FRANCE ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 312. FRANCE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 313. FRANCE ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 314. FRANCE ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 315. FRANCE ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 316. FRANCE ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 317. FRANCE ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 318. FRANCE ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 319. FRANCE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 320. FRANCE ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 321. CANADA ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 322. CANADA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 323. CANADA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 324. CANADA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 325. CANADA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 326. CANADA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 327. CANADA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 328. CANADA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 329. CANADA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 330. CANADA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 331. CANADA ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 332. ITALY ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 333. ITALY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 334. ITALY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 335. ITALY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 336. ITALY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 337. ITALY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 338. ITALY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 339. ITALY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 340. ITALY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 341. ITALY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 342. ITALY ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 343. AUSTRALIA ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 344. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 345. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 346. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 347. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 348. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 349. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 350. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 351. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 352. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 353. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 354. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 355. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 356. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 357. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 358. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 359. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 360. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 361. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 362. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 363. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 364. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 365. BRAZIL ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 366. BRAZIL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 367. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 368. BRAZIL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 369. BRAZIL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 370. BRAZIL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 371. BRAZIL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 372. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 373. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 374. BRAZIL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 375. BRAZIL ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 376. MEXICO ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 377. MEXICO ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 378. MEXICO ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 379. MEXICO ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 380. MEXICO ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 381. MEXICO ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 382. MEXICO ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 383. MEXICO ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 384. MEXICO ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2017-2032 (USD MILLION)
TABLE 385. MEXICO ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 386. MEXICO ORPHAN DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 387. RUSSIA ORPHAN DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 388. RUSSIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 389. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 390. RUSSIA ORPHAN DRUGS MARKET SIZE, BY

Companies Mentioned

  • AbbVie Inc
  • Alexion Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Amgen Inc
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co Ltd
  • F. Hoffmann-La Roche Ltd
  • FGK Clinical Research GmbH
  • Gilead Sciences Inc
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Ipsen Pharma
  • Johnson & Johnson Services Inc
  • Kyowa Kirin Co Ltd
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc
  • Recordati SpA
  • Regeneron Pharmaceuticals Inc
  • Sanofi SA
  • Sarepta Therapeutics Inc
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • UCB SA
  • Ultragenyx Pharmaceutical Inc
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 213.45 Billion
Forecasted Market Value ( USD ) by 2032 $ 421.32 Billion
Compound Annual Growth Rate11.9%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Orphan Drugs Market Size, Share, Trends and Forecast by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region, 2026-2034 - Product Image

Orphan Drugs Market Size, Share, Trends and Forecast by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region, 2026-2034

  • Report
  • 144 Pages
  • Global
From
Orphan Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Orphan Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Orphan Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Orphan Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Orphan Drugs - Global Strategic Business Report - Product Image

Orphan Drugs - Global Strategic Business Report

  • Report
  • 409 Pages
  • Global
From
Orphan Drugs Market Report 2026 - Product Image

Orphan Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Orphan Drug Market

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them. The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives. Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.